Published in Biochim Biophys Acta on June 19, 1993
Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol (1994) 2.18
Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther (2005) 1.81
Modulation of transforming growth factor beta function in hepatocytes and hepatic stellate cells in rat liver injury. Gut (2000) 1.70
Cellular sources of extracellular matrix in hepatic fibrosis. Clin Liver Dis (2008) 1.03
Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am J Pathol (1996) 1.03
Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol (2000) 0.94
Fibronectin: functional character and role in alcoholic liver disease. World J Gastroenterol (2011) 0.89
Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol (2010) 0.86
Regulation of fibronectin splicing in sinusoidal endothelial cells from normal or injured liver. Proc Natl Acad Sci U S A (2004) 0.82
Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodeling. Am J Pathol (2011) 0.81
Cellular fibronectin stimulates hepatocytes to produce factors that promote alcohol-induced liver injury. World J Hepatol (2011) 0.78
Fibronectin Extra Domain A Promotes Liver Sinusoid Repair following Hepatectomy. PLoS One (2016) 0.75
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet (1993) 3.39
Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet (1992) 3.33
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Possible association between Behçet's syndrome and chronic hepatitis C virus infection. N Engl J Med (1995) 2.83
Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis. N Engl J Med (1976) 2.57
Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol (1996) 2.42
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. Proc Natl Acad Sci U S A (1989) 2.40
Genetic characterization of six parasitic protozoa: parity between random-primer DNA typing and multilocus enzyme electrophoresis. Proc Natl Acad Sci U S A (1993) 2.36
Liver-specific antigens of different species. II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol (1974) 2.36
Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol (1997) 2.35
Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology (1999) 2.30
Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand. Nature (1987) 2.28
Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut (1999) 2.24
HLA DRw8 and complement C4 deficiency as risk factors in primary biliary cirrhosis. Gastroenterology (1991) 2.24
Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol (1994) 2.19
Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol (1985) 2.18
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med (1989) 2.15
Endoscopic papillary dilation (EPD) for the treatment of common bile duct stones and papillary stenosis. Endoscopy (1983) 2.05
Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet (2000) 2.01
Studies on the pathogenesis of experimental chronic active hepatitis in rabbits. I. Induction of the disease and protective effect of allogeneic liver specific proteins. Br J Exp Pathol (1974) 2.00
Falsely negative 99mTc-antigranulocyte immunoscintigraphy and positive 99mTc-HMPAO-labelled leukocyte scan in active Crohn's disease. Possible effects of immunosuppressive therapy? Nuklearmedizin (1995) 2.00
Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology (1998) 1.98
Interleukin 6, the third mediator of acute-phase reaction, modulates hepatic protein synthesis in human and mouse. Comparison with interleukin 1 beta and tumor necrosis factor-alpha. Eur J Immunol (1988) 1.98
HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J Hepatol (1997) 1.97
Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1. J Hepatol (1999) 1.89
Expression of the gene of the alpha-smooth muscle-actin isoform in rat liver and in rat fat-storing (ITO) cells. Virchows Arch B Cell Pathol Incl Mol Pathol (1990) 1.83
Differential expression of collagen types I, III, and IV by fat-storing (Ito) cells in vitro. Gastroenterology (1992) 1.78
A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol (1997) 1.78
Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology (1998) 1.65
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol (1998) 1.62
T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol (1994) 1.62
LM-Ag and LSP--two different target antigens involved in the immunopathogenesis of chronic active hepatitis? Clin Exp Immunol (1979) 1.59
Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge. J Hepatol (1995) 1.59
Experimental autoimmune hepatitis: disease induction, time course and T-cell reactivity. Hepatology (1990) 1.57
Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet (1991) 1.56
Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem Cell Biol (2000) 1.55
CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. Am J Pathol (1997) 1.51
A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. Transplantation (2001) 1.51
Functional spectrum of sinusoidal endothelial liver cells. Filtration, endocytosis, synthetic capacities and intercellular communication. J Hepatol (1992) 1.51
T cell receptor triggering induces responsiveness to interleukin 1 and interleukin 2 but does not lead to T cell proliferation. J Immunol (1986) 1.50
Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology (1997) 1.49
Clearance of HCV RNA in a chronic hepatitis C virus-infected patient during acute hepatitis B virus superinfection. Liver (1999) 1.49
In vivo and in vitro binding of IgA to the plasma membrane of hepatocytes. Scand J Immunol (1978) 1.47
[Acute respiratory failure in tropical malaria during pregnancy. Successful treatment using extracorporeal CO2 elimination]. Dtsch Med Wochenschr (1993) 1.45
A new treatment for severe malabsorption due to radiation enteritis. Lancet (1996) 1.45
Autoimmune hepatitis. N Engl J Med (1995) 1.45
Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet (1987) 1.43
Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol (1999) 1.43
Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology (1993) 1.43
Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol (1997) 1.42
No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies. Ann Rheum Dis (1997) 1.41
[Initial clinical experiences with TIPS (transjugular intrahepatic portasystemic stent-shunt)]. Leber Magen Darm (1995) 1.40
Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res (1984) 1.40
[Current theraphy of oesophageal cancer]. Z Gastroenterol (2004) 1.39
[Portal hypertension--pathophysiology and therapeutic approaches]. Z Gastroenterol (1994) 1.38
Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur J Immunol (1992) 1.36
Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem Pharmacol (2000) 1.36
Demonstration of binding sites for IgG Fc and the third complement component (C3) on isolated hepatocytes. J Immunol (1976) 1.36
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods (1996) 1.33
Expression and regulation of the murine serum amyloid A (SAA) gene in extrahepatic sites. J Immunol (1985) 1.33
Accumulation and cellular localization of fibrinogen/fibrin during short-term and long-term rat liver injury. Gastroenterology (1995) 1.32
The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor alpha spots in response to peptide antigens. J Immunol Methods (1997) 1.29
The presence of high amounts of HBV-DNA in serum is associated with suppressed costimulatory effects of interleukin 12 on HBV-induced immune response. J Hepatol (1999) 1.27
Transforming growth factor beta and tumor necrosis factor alpha inhibit both apoptosis and proliferation of activated rat hepatic stellate cells. Hepatology (1999) 1.27
Autoimmune hepatitis following hepatitis A virus infection. J Hepatol (1995) 1.26
The IGF axis and hepatocarcinogenesis. Mol Pathol (2001) 1.26
Association of La and Ro antigens with intracellular structures in HEp-2 carcinoma cells. Proc Natl Acad Sci U S A (1986) 1.26
Endoscopic removal of common bile duct stones through the intact papilla after medical sphincter dilation. Gastroenterology (1985) 1.25
Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy (2003) 1.24
In vitro secretion of anti-GOR protein and anti-hepatitis C virus antibodies in patients with chronic hepatitis C. Gastroenterology (1994) 1.24
Impaired cellular immune responses in chronic renal failure: evidence for a T cell defect. Kidney Int (1986) 1.23
Glial fibrillary acidic protein--a cell type specific marker for Ito cells in vivo and in vitro. J Hepatol (1996) 1.23
Interferon production in patients infected with HIV-1. J Infect Dis (1989) 1.23
In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol (1998) 1.19
Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol (1998) 1.19
Release of glucagon-like peptide-1 (GLP-1) by carbohydrates in the perfused rat ileum. Acta Diabetol (1997) 1.19
Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells. Cancer Immunol Immunother (1994) 1.19
Expression and regulation of cell adhesion molecules by hepatic stellate cells (HSC) of rat liver: involvement of HSC in recruitment of inflammatory cells during hepatic tissue repair. Am J Pathol (1999) 1.18
Human endothelial cells express proteinase 3, the target antigen of anticytoplasmic antibodies in Wegener's granulomatosis. Blood (1993) 1.18
Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther (1998) 1.17
Transforming growth factor beta 1-regulated gene expression of Ito cells. Hepatology (1996) 1.17
Enhanced expression of interferon-regulated genes in the liver of patients with chronic hepatitis C virus infection: detection by suppression-subtractive hybridization. J Virol (2001) 1.17
Synovial fluid-derived Yersinia-reactive T cells responding to human 65-kDa heat-shock protein and heat-stressed antigen-presenting cells. Eur J Immunol (1991) 1.17
Fat storing cells (FSC) of rat liver synthesize and secrete fibronectin. Comparison with hepatocytes. J Hepatol (1987) 1.17
Endoscopic papillary dilatation, a possible alternative to endoscopic papillotomy. Lancet (1982) 1.16
Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J Hepatol (1996) 1.16